Skip to main content
Leanabl Logo

Planning and Feasibility · V&V Testing & Lab Management

Architect a "Test-Once, Submit-Globally" V&V testing program.

Testing against superseded standard editions, omitting IEC 60601-2-x particular standards, or failing to define Essential Performance upfront invalidates months of lab work. We engineer a unified V&V testing matrix across ILAC-MRA, IECEE CB, and OECD GLP laboratories.

Domain Expertise

Deep regulatory authority across every medical device domain

SaMD · AI Digital Health

IEC 62304 & IEC 82304-1 Software Lifecycle · FDA PCCP & Good Machine Learning Practice

Multi-demographic dataset bias control and statistical validation design for Sensitivity, Specificity, and ROC-AUC

Active Devices · Robotics

IEC 60601-1 Ed. 3.2 & IEC 60601-1-2 Ed. 4.1 · IEC 60601-2-XX Particular Standards

Essential Performance definition and worst-case test matrix optimization across FDA, EU Notified Bodies, and MDSAP

Implants · Biomaterials

ISO 10993-1:2018 & ISO 10993-18 E&L · ISO 11135 / 11137 Sterilization & ISO 11607

Biological evaluation plans (BEP), ISO 10993-18 chemical characterization, and toxicological risk assessment (TRA)

In Vitro Diagnostics (IVD)

EU IVDR 2017/746 & FDA IVD Guidance · CLSI EP Guidelines (EP05, EP06, EP12, EP17, EP25)

CLSI-compliant Limit of Detection (LoD), precision, cross-reactivity, interference, and lot-to-lot reproducibility protocols

Proprietary Data & Precedent Validation

Global Standard & National Deviation Matrix + Accredited Lab Capacity DB

100% Optimization of Multi-Market Test Matrices & Worst-Case Sample Grouping

Engineered 4-Stage Workflow

4-Stage Testing Pipeline from Master Test Plan to Audited Final TRFs

Step 01 / 04Stage Gate & Output

Master Multi-Region Test Matrix, Essential Performance & Sample Plan Locked

Incomplete baseline data or misclassified regulatory pathways are the primary drivers of multi-month submission delays. Gate 01 locks the device scope, predicate/standard mapping, and full document inventory before authoring begins.

Verification Baseline

Device description, intended use, existing test reports, and QMS document index

Gate Sign-Off Output

Confirmed classification matrix and locked submission master inventory

Agentic Automation & Platform Integration

Sync Test Protocols & TRFs Directly with PLM V&V and ISO 14971 Risk Controls

Bi-Directional Mapping: Test Clause ↔ Design Output ↔ Risk Control

Automatically links accredited laboratory test results to PLM verification records and ISO 14971 risk control effectiveness proofs.

@Requirements Management— Run "Bi-Directional Mapping: Test Clause ↔ Design Output ↔ Risk Control" across our V&V Testing & Lab Management records and call out the highest-priority compliance findings first.

I'll inspect the linked quality and dossier records against target regulatory standards, then report actionable findings with verified outputs.

Thought for 4.2s · Explored Requirements Management records & 14 regulatory clauses

P1 · Verified Agent Output· Master Multi-Region Test Matrix, Essential Performance & Sample Plan Locked

Automatically links accredited laboratory test results to PLM verification records and ISO 14971 risk control effectiveness proofs. Traceability from specification to verification

Test Sample BOM, Firmware Revision & Configuration Lock

Records the exact hardware BOM and software build of tested units so reviewers never question sample representativeness.

@Risk Management— Run "Test Sample BOM, Firmware Revision & Configuration Lock" across our V&V Testing & Lab Management records and call out the highest-priority compliance findings first.

I'll inspect the linked quality and dossier records against target regulatory standards, then report actionable findings with verified outputs.

Thought for 4.3s · Explored Risk Management records & 14 regulatory clauses

P1 · Verified Agent Output· Automated Pre-Issuance Draft TRF Compliance Audit

Verifies model nomenclature, electrical ratings, Essential Performance pass criteria, and accreditation seals before final TRF sign-off. ISO 14971 risk register linked to design control

Service Specification

Service Scope & Final Deliverables

Scope

End-to-end engineering management from standard mapping and worst-case sample selection to failure debugging and report sign-off.

  • Multi-market standard & National Deviation mapping (IEC 60601-1/1-2, IEC 60601-2-XX, ISO 10993, ISO 11607, CLSI)
  • Worst-case model family grouping and sample quantity optimization to minimize laboratory spend and lead times
  • Accredited laboratory sourcing, quote benchmarking, and slot reservation (IECEE CBTL, ILAC-MRA, FDA ASCA, GLP)
  • Essential Performance definition and pre-compliance test protocol engineering
  • Real-time bench failure root-cause debugging and line-by-line regulatory audit of draft Test Report Forms (TRFs)

Deliverables

Submission-ready test evidence engineered for first-cycle acceptance across global regulatory bodies.

  • Global Master Test Standard & National Deviation Matrix
  • Worst-Case Sample Grouping Rationale & Essential Performance Specification
  • Accredited Laboratory Comparison Matrix & Locked Test Protocols
  • Engineering Failure Resolution & Re-Test Logs (if applicable)
  • Regulatory-Audited Final IECEE CB / ILAC-MRA / GLP Test Report Package
V&V Testing & Lab Management — Service Scope & Final Deliverables
CategoryItem / MilestoneSpecification & Deliverable
ScopeScope 1Multi-market standard & National Deviation mapping (IEC 60601-1/1-2, IEC 60601-2-XX, ISO 10993, ISO 11607, CLSI)
ScopeScope 2Worst-case model family grouping and sample quantity optimization to minimize laboratory spend and lead times
ScopeScope 3Accredited laboratory sourcing, quote benchmarking, and slot reservation (IECEE CBTL, ILAC-MRA, FDA ASCA, GLP)
ScopeScope 4Essential Performance definition and pre-compliance test protocol engineering
ScopeScope 5Real-time bench failure root-cause debugging and line-by-line regulatory audit of draft Test Report Forms (TRFs)
WorkflowStage 1: Master Test Matrix & Essential Performance LockConsolidate target market standard editions and National Deviations while defining Essential Performance and worst-case test samples.
WorkflowStage 2: Accredited Lab Allocation & Protocol Sign-OffBenchmark accredited laboratories on scope, cost, and queue time, then lock the formal Test Plan before sample shipment.
WorkflowStage 3: Active Test Supervision & Failure DebuggingInterface directly with lab engineers during EMC, safety, biocompatibility, and performance runs to resolve anomalies without losing queue slots.
WorkflowStage 4: Draft TRF Regulatory Audit & Final ReleaseAudit draft reports for model nomenclature, firmware revisions, test conditions, and clause completeness before final issuance.
DeliverablesDeliverable 1Global Master Test Standard & National Deviation Matrix
DeliverablesDeliverable 2Worst-Case Sample Grouping Rationale & Essential Performance Specification
DeliverablesDeliverable 3Accredited Laboratory Comparison Matrix & Locked Test Protocols
DeliverablesDeliverable 4Engineering Failure Resolution & Re-Test Logs (if applicable)
DeliverablesDeliverable 5Regulatory-Audited Final IECEE CB / ILAC-MRA / GLP Test Report Package

Frequently Asked Questions

What types of testing do you manage?
We commonly support electrical safety, EMC, biocompatibility, software, cybersecurity, usability, packaging, sterility, and performance testing. The exact scope is defined by device type and target market.
Do you perform the tests yourselves?
No. We plan and manage the testing program, then coordinate with appropriate third-party laboratories when execution is part of the agreed scope.
Can you review a test program that already started?
Yes. We can review existing reports, planned testing, and lab assumptions, then separate what can be reused from what needs justification, supplement, or retesting.
When should we start testing management?
Ideally before design verification starts. Early engagement lets us align standards, samples, acceptance criteria, and documentation before test results become expensive to fix.
How does Leanabl handle agency Additional Information (AI) requests or Notified Body deficiency letters during V&V Testing & Lab Management?
Upon receiving any deficiency notice from FDA, an EU Notified Body, or an international review authority, our engineers dissect the reviewer’s finding against harmonized ISO/IEC clauses and clearance precedents. We separate items resolvable via technical justification from those requiring supplementary bench data, author the formal response dossier, and drive reviewer alignment through closure.
Can we structure one master DHF / IMDRF STED and test campaign to cover FDA, EU MDR, and APAC markets simultaneously?
Yes—that is the core advantage of our universal lifecycle engineering model. By harmonizing FDA eSTAR requirements, EU MDR Annex II/III GSPR checklists, IMDRF STED templates, and multi-country IECEE CB National Deviations before testing or authoring begins, we eliminate redundant laboratory campaigns and prevent region-by-region dossier rewrites.
We have a lean internal RA/QA team—how much bandwidth is required from our R&D engineers?
Our workflow is designed to protect your R&D velocity. Once your team provides baseline engineering inputs (specifications, BOM, architecture diagrams) during Stage 1 intake, Leanabl executes the heavy lifting: standard clause mapping, ISO 14971 risk traceability, regulatory authoring, and laboratory coordination. Your team only reviews and signs off at structured stage gates.
What happens if our hardware, firmware, or software changes during or after the engagement?
We immediately perform a multi-regime regulatory change impact assessment (covering FDA 510(k) modification guidance, EU MDR MDCG 2020-3 significant change criteria, and ISO 13485 design control) to determine whether a formal submission or internal Letter-to-File / QMS update is required. Because deliverables are modularized in our platform, only affected sections require updating.

Know the test plan before samples leave your site.

We define the route, evidence gaps, sequencing, and decision points before labs, samples, and timelines start moving.